A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Latest Information Update: 14 Dec 2020
At a glance
- Drugs NEO-PV 01 (Primary) ; Poly ICLC (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.
- 31 Dec 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 28 Sep 2019 Results assessing personalized neoantigen-targeting vaccines for high-risk melanoma, presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference